Incidence and severity of new onset diabetes associated with SARS-CoV-2 infection

与 SARS-CoV-2 感染相关的新发糖尿病的发病率和严重程度

• 批准号: 10632720
• 负责人: JANE E REUSCH
• 金额: $ 40.6万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10632720
• 关键词: 2019-nCoV; Acute; Address; Adrenal Cortex Hormones; Adult; Affect; Autoimmune; Biochemical Markers; Body mass index; COVID-19; COVID-19 impact; COVID-19 pandemic; COVID-19 patient; COVID-19 severity; Caring; Data; Data Analytics; Data Set; Diabetes Mellitus; Diabetic Ketoacidosis; Diagnosis; Disease; Disease remission; Dyslipidemias; Endothelium; Geography; Glucose; Glycosylated hemoglobin A; Goals; Health Insurance Portability and Accountability Act; Healthcare; Hypertension; Iatrogenesis; Incidence; Infection; Inflammation; Inflammatory; Injury; Inpatients; Insulin; Insulin Resistance; Lipids; Longterm Follow-up; Measurement; Medical Informatics; Natural Immunity; Outcome; Patient risk; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Population; Positioning Attribute; Prognosis; Publishing; Recording of previous events; Research; Risk; SARS-CoV-2 infection; Severities; Site; Structure of beta Cell of islet; Testing; Time; United States National Institutes of Health; Upper Respiratory Infections; Vaccination; Variant; Virus; Work; analytic epidemiology; base; clinical phenotype; clinically significant; cohort; comorbidity; coronavirus disease; data enclave; demographics; diabetogenic; epidemiology study; glycemic control; health care economics; high risk; indexing; male; multidisciplinary; pandemic disease; pediatric patients; post SARS-CoV-2 infection; response; social health determinants; statistics; theories

We of and will use data from t he National COVID Cohort Collaborative (N3C) to “conduct an epidemiologic study diabetes incidence and severity at onset and its potential association with the COVID-19 pandemic the causative virus SARS-CoV-2”The N3C data enclave is the largest publicly available HIPAA-limited data set in U.S. history, over 13 million patients from 72 contributing sites. Due to its scale, demographic and geographic diversity of inpatient and ambulatory data, N3C is uniquely suited to address our research objectives. Hypothesis: COVID-19 infection is associated with an increased incidence of diabetes and severe disease presentation, and there are patient- and infection-related factors that increase patient risk and impact long-term outcomes. Specific Aim 1: Test the hypothesis that COVID-19 infection and infection- related factors are associated with increased incidence of diabetes and severe presentation at diagnosis. We will examine the effect of COVID-19 and infection-related factors, including COVID-19 disease severity, corticosteroid treatment, biochemical markers and virus variant (based on timing in the pandemic or direct measurement), in adult and pediatric patients. We will analyze time to incident diabetes and association of infection-related factors in patients with COVID-19 infection compared to matched controls with acute upper respiratory infection (AURI). Specific Aim 2: Test the hypothesis that COVID-19 infection and patient- related factors are associated with increased incidence of diabetes and severe presentation at diagnosis. We will explore the effect of patient-related factors, including demographics, BMI, HbA1c and lipids prior to COVID-19, comorbidities (e.g., dyslipidemia, hypertension, autoimmune/inflammatory conditions), vaccination status, medication use and social determinants of health (SDOH) on incident diabetes and severe disease presentation in adult and pediatric patients with COVID-19 and matched controls with acute upper respiratory infection (AURI). Specific Aim 3: Test the hypothesis that patients with incident diabetes after COVID-19 will have worse long-term outcomes compared to those without COVID-19 infection. We will compare outcomes in adult and pediatric patients with incident diabetes diagnosed within 90 days of their index date with prior COVID-19 infection compared to matched controls with AURI. Long-term outcomes over 12-18 months will include diabetes remission, glycemic control and treatment with insulin and other glucose lowering medications. Impact: The NIH-supported N3C Data Enclave, with its demographic and geographic diversity, was created precisely to address the long-term consequences of the pandemic. The proposed studies will 1. Establish and characterize increased incidence and severity of diabetes with COVID-19 infection; 2. Elucidate infection- and patient-related factors associated with incident diabetes and severe disease presentation at diagnosis, and 3. Evaluate the long-term outcomes of patients with incident diabetes in a nationally representative population.

我们 的 和 我将使用国家新冠肺炎队列协作组织（N3 C）的数据进行流行病学研究 糖尿病发病率和发病时的严重程度及其与COVID-19大流行的潜在关联 致病病毒SARS-CoV-2“N3 C数据飞地是最大的公开可用的HIPAA有限 美国历史上的数据集，来自72个贡献站点的1300多万患者。由于其规模、人口和 由于住院和门诊数据的地理多样性，N3 C非常适合实现我们的研究目标。 假设：COVID-19感染与糖尿病发病率增加和严重 疾病表现，并且存在增加患者风险的患者和感染相关因素， 影响长期成果。具体目标1：检验COVID-19感染和感染- 相关因素与糖尿病发病率的增加和诊断时的严重表现有关。 我们将研究COVID-19和感染相关因素的影响，包括COVID-19疾病的严重程度， 皮质类固醇治疗、生化标志物和病毒变体（基于大流行的时间或直接 测量），在成人和儿科患者中。我们将分析发生糖尿病的时间以及 COVID-19感染患者的感染相关因素与急性上呼吸道感染的匹配对照相比 呼吸道感染（AURI）。具体目标2：检验COVID-19感染和患者- 相关因素与糖尿病发病率的增加和诊断时的严重表现有关。 我们将探讨患者相关因素的影响，包括人口统计学、BMI、HbA 1c和血脂， COVID-19、合并症（例如，血脂异常、高血压、自身免疫性/炎症性疾病）、疫苗接种 糖尿病和严重疾病发病率、药物使用和社会健康决定因素（SDOH） COVID-19成人和儿童患者以及匹配的急性上呼吸道疾病对照组的临床表现 感染（AURI）。具体目标3：检验COVID-19后发生糖尿病的患者 与未感染COVID-19的人相比，长期结果会更差。我们将比较 在索引日期后90天内诊断为偶发糖尿病的成人和儿童患者的结局， 既往COVID-19感染与AURI的匹配对照相比。12-18个月的长期结果将 包括糖尿病缓解、血糖控制和用胰岛素和其它降糖药物治疗。 影响：NIH支持的N3 C数据飞地，其人口和地理多样性，被创建 正是为了解决这一流行病的长期后果。这些研究将1。树立和 表征伴随COVID-19感染的糖尿病的发病率和严重程度增加; 2.阐明感染-和 与糖尿病事件和诊断时的严重疾病表现相关的患者相关因素，以及3. 在具有全国代表性的人群中评价新发糖尿病患者的长期结局。